List view / Grid view
An analysis of SARS-CoV-2 has allowed researchers to identify epitopes recognised by a large fraction of COVID-19 patients, with 10 that could be targeted by antibodies.
Scientists have found a hormone peptide called YY that presents a promising drug target for malabsorption in babies.
The Spike (S) protein is a promising drug target in the quest to develop vaccines and antivirals for SARS-CoV-2 to treat and prevent COVID-19. Intra-protein interaction energy landscape mapping efforts have recently identified key interactions that may be crucial for the S protein’s ability to bind to receptor proteins on…
A possible treatment and vaccine combination for COVID-19 has shown positive results in pre-clinical studies using human cells.
The novel nanoparticle delivered Mp6 peptide was able to inhibit thrombosis and reduce inflammation without increasing the risk of bleeding in mice after heart attacks.
Despite hundreds of off-the-shelf treatments, cancer remains the second leading cause of death globally.
Scientists have developed a new antimicrobial peptide therapy named D8 with high efficacy and low toxicity in mice which could be used to fight lung infections.
Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
Combining the chlorotoxin peptide with conventional CAR structures, researchers have created a new CAR T cell therapy that has successfully combatted glioblastomas in mice.
Researchers have used a peptide called D6PV to lower triglycerides in mouse models, which could be used as a therapy for high triglyceride-induced acute pancreatitis in humans.
A key receptor has been examined for the first time at high resolution which could lead to better treatments for conditions such as type 2 diabetes.
A new technique has been developed which has the potential to harness bacteria to produce billions of different drug candidates to treat diseases like cancer.
A study has identified a protein complex elevated in PTSD patients and developed a peptide to disrupt it, preventing the recall of fear memories in early tests and paving the way for new therapies.
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
